Bam Adebayo (Miami Heat) with a dunk vs the Phoenix Suns, 04/13/2021
Bam Adebayo (Miami Heat) with a dunk vs the Phoenix Suns, 04/13/2021
New York, New York--(Newsfile Corp. - May 7, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of XL Fleet Corp. (NYSE: XL) between October 2, 2020 and March 2, 2021, inclusive (the "Class Period"), of the important May 7, 2021 lead plaintiff deadline.SO WHAT: If you purchased XL Fleet securities during the Class Period you may be entitled to compensation without payment of any out ...
The girl, reported to be aged 11 or 12, shot and wounded two fellow students and a member of staff.
Employers hired 266,000 people last month, figures show, despite a $1.9tn stimulus package.
Fire broke out Friday in a London apartment tower which has cladding similar to that used on another housing block in the city where 72 people died in a 2017 blaze. London Fire Brigade said about 125 firefighters tackled a fire that spread to three floors of a 19-story building in the city’s Docklands. The fire brigade said “firefighters wearing breathing apparatus have carried out multiple rescues.”
The Andersons, Inc. (Nasdaq: ANDE) has named Gary Douglas to the company's Board of Directors, effective May 7, 2021.
Zoned Properties Expands Real Estate Services with PropTech Data Projects
Major players in the big data and analytics services market are IBM Corporation, Oracle Corporation, Microsoft Corporation, SAP SE, TIBCO Software Inc. , Teradata Corporation, Amazon Web Services, SAS Institute Inc.New York, May 07, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Big Data and Analytics Services Global Market Report 2021: COVID 19 Growth And Change to 2030" - https://www.reportlinker.com/p06070249/?utm_source=GNW , Tableau Corporation and Alteryx.The global big data and analytics services market is expected grow from $73.26 billion in 2020 to $76.1 billion in 2021 at a compound annual growth rate (CAGR) of 3.9%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $117.19 billion in 2025 at a CAGR of 11%.The big data and analytics services market consists of sales and related services that are used in customer analytics, supply chain analytics, marketing analytics, spatial analytics, transportation analytics, risk and credit analytics. Big data analytics services examine vast volumes of data to uncover hidden trends, similarities and other insights and allow companies to analyse and optimize their data to find new opportunities.The increasing growth of integration of internet of things in daily lives is a key factor driving the growth of the big data and analytics services market.When organizations take a hold of the data for the purpose of research, IoT serves as a major source for that data and this is the point where the position of big data in IoT comes into the picture.IoT devices produce a huge amount of unstructured data, which are stored in the big data network and this data largely depends on 3V factors such as volume, velocity and variety.About 44 trillion gigabytes of data is expected to be generated by the Internet of Things by year 2020.With the increasing number of connected devices, by 2020, more than 10 billion sensors and computers will be connected to the Internet. Therefore, increasing growth of internet of things is expected to drive the growth of the big data and analytics services market.The issues with integration of information collected from various data sources is a key factor hampering the growth of the big data and analytics services market.Big Data Integration integrates data from a variety of sources and software formats and offers a converted and coherent view of the collected data to the consumers.Data from a wide variety of sources use different priorities and rates and can be easily de-synchronized from the source system.For instance, many companies collect data from various sources such as customer relationship management (CRM) systems, enterprise resource planning (ERP) systems and specific types of data stored in different formats.However, such data variability could not be enabled by a single integration platform, everything must be homogenized for accurate and efficient analysis. Therefore, issues with integration of information collected from various data sources is expected to limit the growth of the big data and analytics services market.The big data and analytics services market covered in this report is segmented by deployment mode into on-premise, cloud, others and by application into customer analytics, supply chain analytics, marketing analytics, pricing analytics, spatial analytics, workforce analytics, risk & credit analytics, transportation analytics., others.The continuous intelligence is a key trend in the big data and analytics services market.Continuous intelligence is a device that has combined real-time analytics with business operations, it makes use of historical and current knowledge to improve decision-making or to help make decisions.It leverages a variety of technologies such as optimization, business rule management, event stream processing, augmented analytics, and machine learning.Many companies should leverage continuous intelligence to achieve (or retain) a competitive advantage throughout 2020.Also, Gartner expects that by 2022 more than 50 per cent of the modern business structure will use continuous intelligence that uses real-time context data to improve decisions.In January 2019, Alibaba Group, a China-based company, specializing in e-commerce, retail, internet, and technology acquired Data Artisans for $103M.Through this acquisition Data Artisans business reached new horizons with its open source technology, including moves to expand to new areas that have not explored in the past.Data Artisans, a Berlin-based start-up that provides distributed systems and large-scale data streaming services for enterprises.Read the full report: https://www.reportlinker.com/p06070249/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
BentrioTM meets primary efficacy endpoint in clinical evaluation in allergic rhinitisClinically relevant and significant reduction in nasal symptomsSuperior efficacy ratings by patients and clinicians Pre-submission meeting with FDA supports 510(k) regulatory pathway Hamilton, Bermuda, May 7, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, and its affiliate Altamira Medica Ltd. today announced additional details on the outcomes from the clinical investigation of its BentrioTM nasal spray in allergic rhinitis and provided an update on the regulatory pathway in the US for the intended use in allergy. BentrioTM effectively alleviates allergy symptoms in clinical pollen challenge BentrioTM was tested in an open-label randomized cross-over trial in 36 patients with allergic rhinitis to grass pollen. Study participants were administered a single dose of BentrioTM nasal spray or a comparator product prior to controlled pollen exposure for four hours in an allergen challenge chamber. The challenge was repeated with the alternate treatment following a wash-out period. The study demonstrated a rapid onset and long durability of Bentrio’s protective effect, established substantial equivalence to the marketed comparator with superior efficacy ratings by patients and clinicians, and showed good tolerability. Under treatment with BentrioTM, participants reported a mean increase in the Total Nasal Symptom Score (TNSS; averaged over 4 hours in 20 minute intervals) of 4.75 points, which was 1.11 points and thus significantly below TNSS levels when exposed to pollen without nasal spray protection (ANCOVA least square means; 95% confidence interval, CI: -1.61 to -0.61). A 1-point reduction in the TNSS is considered clinically relevant. 31.4% of study participants rated the efficacy of BentrioTM as “good” or “very good”, while study investigators provided such rating for 45.7% of participants. Under treatment with the comparator product, a powder spray based on hydroxypropylmethylcellulose (HMPC), the TNSS increased on average by 5.14 points, which was 0.71 points lower than when unprotected (CI: -1.21 to -0.21). 14.3% of study participants rated the efficacy of the comparator as “good” or “very good”, while study investigators provided such rating for 25.0% of participants. BentrioTM showed significantly lower increases in the TNSS than HPMC especially during the early phase of pollen exposure, reaching clinical relevance and suggesting a rapid onset of action. As previously announced, BentrioTM met the primary endpoint of substantial equivalence in the change of TNSS relative to HPMC, which serves as a predicate device for the planned 510(k) submission to the US Food and Drug Administration (FDA). Final analyses show a difference of 0.4 points in favor of BentrioTM (CI -0.89 to 0.10), confirming non-inferiority. Proof of substantial equivalence to the predicate device is a key requirement for market clearance in the US under the 510(k) regulatory pathway. In addition, the study provided further evidence for the favorable safety profile of BentrioTM; with the exception of one case, all study participants rated the tolerability favorably. Pre-submission meeting with FDA On May 6, 2021, Altamira Medica met with the FDA for a pre-submission meeting relating to a 510(k) pre-market notification application. The Company expects to request regulatory clearance for BentrioTM for the intended use in allergy under the 510(k) pathway. During the meeting, the Company obtained important information needed to help finalize the submission package. Importantly, the Agency indicated that the design of the pollen challenge study appeared appropriate to support the planned 510(k) submission. “We are very delighted to have reached further important milestones with our BentrioTM program”, commented Thomas Meyer, Auris Medical’s founder, Chairman and CEO. “We are very delighted by the positive outcomes from the pollen chamber study, where BentrioTM provided rapid and effective protection for four hours of challenging allergen exposure. In addition, we very much appreciated the FDA’s feedback during the pre-submission meeting and feel well positioned to advance the preparations for a 510(k) submission. At the same time, we are on track to meet the essential requirements for marketing the product in Europe under the CE mark shortly. We intend to launch the commercialization of BentrioTM in selected European countries towards the end of June 2021 through various on- and offline distribution channels. Launch preparations are in full swing.” About BentrioTM BentrioTM (AM-301) is a drug-free nasal spray for personal protection against airborne viruses and allergens. Upon application into the nose, BentrioTM forms a protective gel layer on the nasal mucosa. This thin film is designed to prevent the contact of viruses or allergens with cells; in addition, the composition serves to bind such particles and help with their discharge and to humidify the nasal mucosa. Together, this is designed to reduce the risk of upper respiratory tract viral infections and promote alleviation of allergic symptoms. About Auris Medical Auris Medical is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. The Company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase 2) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201, post Phase 1b). Through its affiliate Altamira Medica, the Company is developing a nasal spray for protection against airborne viruses and allergens BentrioTM (AM-301). In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol “EARS.” Forward-looking Statements This press release may contain statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Auris Medical’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may”, “might”, “will”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “projects”, “potential”, “outlook” or “continue”, or the negative of these terms or other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the approval and timing of commercialization of AM-301, Auris Medical’s need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Auris Medical’s product candidates, the clinical utility of Auris Medical’s product candidates, the timing or likelihood of regulatory filings and approvals, Auris Medical’s intellectual property position and Auris Medical’s financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Auris Medical’s capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption “Risk Factors” in Auris Medical’s Annual Report on Form 20-F for the year ended December 31, 2020, and in Auris Medical's other filings with the SEC, which are available free of charge on the Securities Exchange Commission's website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Auris Medical or to persons acting on behalf of Auris Medical are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Auris Medical does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. Investor contact: firstname.lastname@example.org
Toronto, Ontario--(Newsfile Corp. - May 7, 2021) - 3iQ Corp. ("3iQ"), the largest digital asset manager in Canada with more than C$3.5 billion in Assets Under Management ("AUM"), is pleased to announce the 3iQ CoinShares Bitcoin ETF (the "ETF") has surpassed C$1 billion in AUM."Reaching $1 billion in only three weeks speaks to the enormous market demand for bitcoin," said Fred Pye, Chairman & CEO of 3iQ. "The pace of its growth is yet ...
Royal Gold Presenting at the BofA Global Metals, Mining & Steel Virtual Conference 2021
Greensill Capital's UK business had $17.7 billion in assets under management at March 8, of which $3.7 billion has been collected as of April 16, its administrators Grant Thornton said on Friday. The supply chain finance firm, which lent money to firms by buying their invoices at a discount, collapsed in March 2021 after insurers pulled their cover. The administrators proposed in a statement that the administration would end with the voluntary liquidation or dissolution of Greensill Capital UK and Greensill Capital Management UK, after a sale attempt fell through earlier this year.
The U.S. economy added disappointing 266K jobs in April even as states relaxed business restrictions and vaccinations increased. Unemployment rose to 6.1%.
Forty adults and four children have been treated after the blaze at New Providence Wharf near Canary Wharf.
Firsthand Capital Management collected $33.8M in fees over nearly ten-year period during which the SVVC stock price declined 78%.Rawleigh Ralls, a professional investor/portfolio manager and long-time stockholder of SVVC, owns approximately 3.7% of SVVC common stock.MR. RALLS URGES SVVC STOCKHOLDERS TO VOTE IN FAVOR OF PROPOSAL 3, SEEKING TO TERMINATE THE INVESTMENT ADVISORY AND MANAGEMENT AGREEMENTS BETWEEN SVVC AND FIRSTHAND CAPITAL MANAGEMENT, AT SVVC’S MAY 25TH ANNUAL MEETING. BOULDER, Colo. and SAN JOSE, Calif., May 07, 2021 (GLOBE NEWSWIRE) -- Rawleigh Ralls, a long-term investor and beneficial owner of 3.7% of Firsthand Technology Value Fund, Inc. (NASDAQ: SVVC), today announced his strong and urgent support of a binding proposal to terminate the investment advisory and management agreements between SVVC and Firsthand Capital Management, Inc., which is being submitted for consideration by stockholders at the Fund’s 2021 Annual Meeting on May 25, 2021. Mr. Ralls has been a stockholder of SVVC since 2013 and currently owns 3.7% of SVVC’s outstanding common stock. He is an experienced board member and a successful investor/portfolio manager, who has founded several investment funds.Mr. Ralls has known Kevin Landis, Chairman of the Board, CEO and President of SVVC, for over 7 years and serves on the board of IntraOp Medical, one of SVVC’s portfolio companies. Over the past ten years Mr. Landis has had ample opportunity to prove his competence in managing the Fund’s investment portfolio, but the results clearly demonstrate that he has failed in this role.Mr. Ralls is voting AGAINST the election of both board members up for re-election, Mr. Burglin and Mr. Yee, because he holds the board responsible for SVVC’s performance and not acting to change the Fund’s management structure and advisory relationship.Mr. Ralls is urging all SVVC stockholders to SUPPORT a BINDING proposal to TERMINATE the investment advisory and management agreements between Firsthand Technology Value Fund, Inc. and Firsthand Capital Management, Inc. If the investment advisory and management agreements with Firsthand Capital Management are terminated, Mr. Ralls will work with other stockholders and the current or a newly appointed board of SVVC to maximize the value of the current portfolio.Mr. Ralls is available to speak with any stockholder who would like a more detailed description of his experience with Mr. Landis and Firsthand Capital Management and why he believes Mr. Landis and Firsthand Capital Management are unqualified to continue in their current roles. He is also interested in sharing his ideas on how to help SVVC realize its potential while reducing fees and expenses. Mr. Ralls can be reached via email at email@example.com The following are Mr. Ralls observations based on his investment experience and facts from SVVC’s public filings: 1.SVVC’s performance has been abysmal and is even more alarming given that it occurred during one of the biggest bull markets in recent history. 2.As illustrated in SVVC’s recent Form 10-K, a $10,000 investment in SVVC stock at its inception on April 18, 2011 would be down 78% in value and worth just $2,190 on December 31, 2020, while investments in the broader markets like the SP500 and Nasdaq are up 350-500% over the same period. According to cfainstitute.org data, venture capital fund returns are even higher. 3.Yet according to SVVC’s annual 10-K filings, Mr. Landis’ company, Firsthand Capital Management, has been paid over $33.8M in advisory fees over the last 10 years, while the Fund has suffered losses of well over $100M in total assets from its peak in 2014. 4.Mr. Landis’ investment selection and stewardship has been dreadful with an intolerable number of his substantial investments resulting in “ZEROS.” Below are a few examples: InvestmentTotal InvestmentInvestment DurationYear Written Down to Zero QMAT$20.7M~7 years2019 Telepathy$7.95M~ 5 years2019 Aliphcom$10.1M~ 4 years2017 VuFine$5M~ 4 years2019 Total$43.75M 5.The current portfolio holdings performance has also been dismal. Below are the top portfolio positions using year-end valuations vs. total invested capital as of December 31, 2020 (Form 10-K). Pivotal Systems – Initial investment in 2012, total invested by SVVC ~$3.6mm, current value $22.5mm, UP 625%.IntraOp Medical – Initial investment of $26mm in 2013, total invested by SVVC ~$50mm, current value $25mm, DOWN $25mm, or 50% from initial investment, approximately 8 years ago.WrightSpeed – Initial investment $6mm in 2013, total invested ~$36mm, current value $23mm, DOWN $13mm, or 36% from initial investment almost 8 years ago.Revasum – Initial investment 2016, total invested by SVVC ~$13.5mm, current value $12.6mm, DOWN 6.6% over the investment period.Hera Systems – Initial investment of $2mm in 2015, total invested by SVVC ~$11.2mm, current value $3.6mm, DOWN $7.6mm, or 68% from initial investment.SVXR – Initial (and total) investment $4.1mm in 2016 by SVVC, current value $5.38mm, UP 32%.Silicon Genesis – Initial investment $2.4mm in 2011, total investment by SVVC of $8.4mm, current value $1.33mm, DOWN 84% from initial investment. The only real winner in the current portfolio, Pivotal Systems, looks to have been Firsthand’s ‘source of funds’ over the last year or longer. Mr. Landis has been selling this winner so he can re-invest in the portfolio’s losers. One year ago, the Fund owned 45M shares of Pivotal Systems vs. the 31M shares owned as of December 31, 2020. Mr. Landis has a long history of selling his winners to prop up his losers (the portfolio once included FB, NFLX, NUTX, ROKU, TWTR and WKDY). In summary, the portfolio’s long-term results strongly confirm that Mr. Landis and his firm’s management contract should be terminated. The the current board should easily be able to manage the portfolio in the interim while seeking an alternative management solution, and Mr. Ralls is willing to volunteer his time, resources and experience to assist with this process at no cost to SVVC stockholders. Mr. Ralls has over 30 years experience in the investment community, including an eight-year career at Goldman Sachs and as co-founder of two investment funds, Precept Capital Management and Lacuna Capital LLC. He is currently a director on six company boards, including one public (Tucows, Inc. Nasdaq: TCX) and five private companies in the software and technology space. Mr. Ralls has been on numerous other company boards, raised considerable investment capital and advised many public and private company management teams. Mr. Ralls graduated from the University of Arkansas in 1984 and received an MBA from Southern Methodist University. IMPORTANT INFORMATION CONCERNING THIS COMMUNICATIONThis press release is being issued pursuant to Rule 14a-2(b)(1) promulgated under the Securities Exchange Act of 1934. This is not a solicitation of authority to vote your proxy. I am not asking for your proxy card and will not accept proxy cards if sent. The cost of this communication is being borne entirely by Rawleigh Ralls. Contact:Rawleigh Rallsrallsrawleigh@gmail.com
There were some upsides to traveling during the COVID pandemic: Fares were dirt cheap, flights weren't crowded and passengers sailed through TSA.
Ascend Wellness Holdings, Inc. ("AWH" or the "Company") (CSE: AAWH.U), a multi-state, vertically integrated cannabis operator, today announced that the Underwriters (as defined below) of its previously announced initial public offering of Class A common stock (the "Offering") have fully exercised and closed their option to purchase an additional 1,500,000 shares of Class A common stock at the Offering price of US$8.00 per share for additional gross proceeds to the Company of US$12,000,000. After giving effect to the full exercise of the over-allotment option, the total number of shares sold by AWH in the Offering increased to 11,500,000 shares and gross proceeds increased to US$92,000,000.
A group of homeowners recently won a large payout from Network Rail after Japanese Knotweed spread onto their property from a nearby train track.
Cinemark has reached new agreements with the five major studios that could help formalize a shorter theatrical window. Terms of the deal were not disclosed, but it comes as COVID-19 has reshaped the amount of time that films show exclusively on the big screen before making their home entertainment debuts. The company signed a deal […]
Brazilian retail sales fell in March for a third month in four, official figures showed on Friday, but held up far stronger than economists had feared and expanded solidly on the same month last year. Statistics agency IBGE said sales fell in seven of the eight categories surveyed in March, led by a 41.5% fall in clothing and footwear, and a 22.0% fall in furniture and electrical goods. The overall figures were buttressed by a 3.3% rise in food, drink and tobacco sales, IBGE figures showed.
SHANGHAI, China, May 07, 2021 (GLOBE NEWSWIRE) -- Baozun Inc. (NASDAQ: BZUN and HKEX: 9991) (“Baozun” or the “Company”), the leading brand e-commerce service partner that helps brands execute their e-commerce strategies in China, announced today that the following shareholder resolutions were adopted and passed at its annual general meeting of shareholders held on May 7, 2021 in Shanghai, China: BY WAY OF A SPECIAL RESOLUTION, that the Fourth Amended and Restated Memorandum and Articles of Association currently in effect be amended and restated by the deletion in their entirety and the substitution in their place of the Fifth Amended and Restated Memorandum and Articles of Association of the Company in the form attached as Annex A to the proxy statement, and reflecting the updates as detailed in the proxy statement;BY WAY OF AN ORDINARY RESOLUTION, that the appointment of Deloitte Touche Tohmatsu Certified Public Accountants LLP and Deloitte Touche Tohmatsu as the Company’s independent registered public accounting firm to audit the Company’s consolidated financial statements filed with the U.S. Securities and Exchange Commission and The Stock Exchange of Hong Kong Limited, respectively, for the year ended December 31, 2020 and the authorization for the directors of the Company to determine the remuneration of the Company’s independent registered public accounting firms be authorized, approved and ratified;BY WAY OF AN ORDINARY RESOLUTION, that the appointment of Deloitte Touche Tohmatsu Certified Public Accountants LLP and Deloitte Touche Tohmatsu as the Company's independent registered public accounting firm to audit the Company's consolidated financial statements to be filed with the U.S. Securities and Exchange Commission and The Stock Exchange of Hong Kong Limited, respectively, for the year ending December 31, 2021 and the authorization for the directors of the Company to determine the remuneration of the Company’s independent registered public accounting firms be authorized, approved and ratified;BY WAY OF AN ORDINARY RESOLUTION, that Ms. Jessica Xiuyun Liu be re-elected as a director of the Company; andBY WAY OF AN ORDINARY RESOLUTION, that subject to the approval of resolutions 1 – 4 above, each director or officer of the Company be authorized to take any and every action that might be necessary, appropriate or desirable to effect resolutions 1 – 4 as such director or officer, in his or her absolute discretion, thinks fit. About Baozun Inc. Baozun Inc. is the leader and a pioneer in the brand e-commerce service industry in China. Baozun empowers a broad and diverse range of brands to grow and succeed by leveraging its end-to-end e-commerce service capabilities, omni-channel coverage and technology-driven solutions. Its integrated one-stop solutions address all core aspects of the e-commerce operations covering IT solutions, online store operations, digital marketing, customer services, and warehousing and fulfillment. For more information, please visit http://ir.baozun.com For investor and media inquiries, please contact: Baozun Inc.Ms. Wendy SunEmail: firstname.lastname@example.org ChristensenIn ChinaMr. Rene VanguestainePhone: +852-6686-1376E-mail: email@example.com In U.S.Ms. Linda BergkampPhone: +1-480-614-3004Email: lbergkamp@ChristensenIR.com